The shadow of generic competition has long loomed over copyright’s blockbuster drug, Sildenafil, raising questions about the prospects of connected pharmaceutical holdings. While initial times saw substantial gains, the exclusivity expiration has allowed the way for less expensive alternatives, likely reducing earnings and posing a genuine hazard